Piramal Pharma

Why is Piramal Pharma Ltd falling/rising?

As of 30-Jul, Piramal Pharma Ltd's stock price is at Rs 196.85, having risen 8.85% over the past week and 17.03% over the last month, significantly outperforming the Sensex. Despite positive momentum and increased investor interest, the company faces challenges like weak long-term fundamentals and a high debt-to-EBITDA ratio.

As of 30-Jul, Piramal Pharma Ltd's stock price is rising, currently at Rs 196.85, reflecting a change of 1.1 (0.56%) upward. The stock has shown strong performance over the past week, with an increase of 8.85%, significantly outperforming the Sensex, which rose by only 2.01% during the same period. Over the last month, the stock has gained 17.03%, while the Sensex has only increased by 1.90%. <BR><BR>The stock has been on a positive trajectory, gaining for six consecutive days and achieving a total return of 11.18% during this period. Additionally, it reached an intraday high of Rs 202.2, marking a 3.3% increase. Piramal Pharma is also trading above its moving averages across various time frames, indicating a bullish trend. <BR><BR>Investor participation has risen, with a delivery volume of 57.33 lacs on July 29, which is 4.76% higher than the five-day average. This increase in trading activity suggests growing interest in the stock. Furthermore, the company has a high institutional holding of 27.09%, which often reflects confidence from investors with substantial resources to analyze the company's fundamentals.<BR><BR>Despite these positive indicators, it is important to note that the company faces challenges, such as weak long-term fundamental strength and a high debt-to-EBITDA ratio. However, the current momentum in the stock price appears to be driven by recent performance and increased investor interest.

Which are the latest news on Piramal Pharma?

Are Piramal Pharma Ltd latest results good or bad?

Piramal Pharma Ltd's latest results show a significant net loss of ₹69.39 crore, reflecting deepening profitability challenges, despite a 17.39% year-on-year revenue growth. Overall, the mixed results indicate more negative trends, and investors should remain cautious.

Piramal Pharma Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net loss of ₹69.39 crore for Q1 FY27, which is a significant increase in losses compared to the previous quarter, reflecting a 685.84% decline QoQ. This indicates that the company's profitability challenges are deepening.<BR><BR>On the other hand, the company achieved a revenue growth of 17.39% year-on-year, with net sales reaching ₹2,269.92 crore. This growth was driven by demand in its Contract Development and Manufacturing Organisation (CDMO) and Consumer Healthcare segments. However, it is important to note that there was a sequential decline of 17.51% from the previous quarter, highlighting volatility in sales.<BR><BR>The operating margin improved to 8.60%, up 308 basis points year-on-year, but this is still significantly lower than the 16.74% margin achieved in the previous quarter. Additionally, the interest coverage ratio of 0.66x indicates that the company is struggling to meet its debt obligations, which raises concerns about its financial health.<BR><BR>Overall, while there are positive signs in terms of revenue growth and operational improvements, the widening losses and ongoing financial challenges suggest that the results are more negative than positive at this time. Investors should be cautious and monitor the company's ability to turn around its profitability in the coming quarters.

Should I buy, sell or hold Piramal Pharma Ltd?

What does Piramal Pharma do?

Piramal Pharma Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, offering a range of products and services. As of March 2026, it reported net sales of ₹2,752 Cr and a net loss of ₹9 Cr, with a market cap of ₹22,413 Cr.

Overview: <BR>Piramal Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry as a small-cap company, offering a portfolio of differentiated products and services through comprehensive manufacturing capabilities.<BR><BR>History: <BR>Piramal Pharma Limited was incorporated on March 4, 2020, as a Public Limited Company. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2,752 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -9 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 22,413 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.06% <BR>Debt-Equity: 0.53 <BR>Return on Equity: -1.59% <BR>Price to Book: 2.75<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Piramal Pharma?

As of 10th June, Piramal Pharma Ltd has a market capitalization of 22,413.00 Cr and reported net sales of 8,869.07 Cr with a loss of 325.94 Cr over the latest four quarters. Shareholder's funds are 8,125.47 Cr and total assets amount to 15,284.46 Cr.

As of 10th June, Piramal Pharma Ltd has a market capitalization of 22,413.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Piramal Pharma reported net sales of 8,869.07 Cr. However, the company experienced a loss of 325.94 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's funds are reported at 8,125.47 Cr, while total assets amount to 15,284.46 Cr.

Who are in the management team of Piramal Pharma?

The management team of Piramal Pharma includes Chairperson Nandini Piramal, CEO Peter D. DeYoung, CFO Vivek Valsaraj, and Directors Neeraj Bharadwaj and Nathalie Leitch, along with several independent directors. Tanya D'Costa serves as the Company Secretary and Compliance Officer.

The management team of Piramal Pharma includes the following key individuals:<BR><BR>1. **Nandini Piramal** - Chairperson<BR>2. **Peter D. DeYoung** - Executive Director & CEO<BR>3. **Vivek Valsaraj** - Executive Director & CFO<BR>4. **Neeraj Bharadwaj** - Director<BR>5. **Nathalie Leitch** - Director<BR><BR>Additionally, there are several independent directors on the board:<BR><BR>- **Jairaj Purandare**<BR>- **S. Rama Dorai**<BR>- **Peter Stevenson**<BR>- **Sridhar Gorthi**<BR>- **Vibha Paul Rishi**<BR><BR>Tanya D'Costa serves as the Company Secretary and Compliance Officer. This diverse management team brings a wealth of experience to the company.

Who are the peers of the Piramal Pharma?

Piramal Pharma's peers include J B Chemicals, Emcure Pharma, Wockhardt, Acutaas Chemical, Sai Life, Neuland Labs, AstraZeneca, Pfizer, and OneSource Specialty. While Acutaas Chemical shows the highest 1-year return at 186.73%, Piramal Pharma has the lowest at -19.80%, indicating weaker performance relative to its peers.

Peers: The peers of Piramal Pharma are J B Chemicals &, Emcure Pharma, Wockhardt, Acutaas Chemical, Sai Life, Neuland Labs., Astrazeneca Phar, Pfizer, and OneSource Speci.<BR><BR>Quality Snapshot: Excellent management risk is observed at Acutaas Chemical, Emcure Pharma, J B Chemicals &, and Neuland Labs., while Average management risk is found at Wockhardt, Piramal Pharma, and Sai Life. Good growth is noted at Acutaas Chemical, Emcure Pharma, Neuland Labs., and Piramal Pharma, while Below Average growth is seen at Astrazeneca Phar and Pfizer. Excellent capital structure is present at Acutaas Chemical, Sai Life, and Neuland Labs., while Below Average capital structure is noted at Piramal Pharma and OneSource Speci.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 186.73%, while Piramal Pharma has the lowest at -19.80%. This indicates that Piramal Pharma's performance is significantly worse compared to its peers. Additionally, Wockhardt, Astrazeneca Phar, Pfizer, and OneSource Speci. have negative six-month returns.

Is Piramal Pharma technically bullish or bearish?

As of December 3, 2025, Piramal Pharma's technical trend has shifted to bearish, supported by negative indicators from MACD, moving averages, Bollinger Bands, and a lack of positive signals from RSI and OBV.

As of 3 December 2025, the technical trend for Piramal Pharma has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators. The weekly MACD is bearish, and the daily moving averages also reflect a bearish trend. Bollinger Bands confirm bearish conditions on both weekly and monthly time frames. The Dow Theory indicates a mildly bearish stance on the weekly and monthly charts. Overall, the lack of positive signals from the RSI and OBV further supports the bearish outlook.

How has been the historical performance of Piramal Pharma?

Piramal Pharma has shown a generally upward trend in net sales and operating profit from Mar'22 to Mar'25, despite fluctuations in profit before and after tax. Total liabilities and assets have increased, indicating growth, while cash flow has been variable.

Answer:<BR>The historical performance of Piramal Pharma shows a fluctuating yet generally upward trend in key financial metrics over the past few years.<BR><BR>Breakdown:<BR>Piramal Pharma's net sales have increased from 6,559.10 Cr in Mar'22 to 9,151.18 Cr in Mar'25, reflecting a consistent growth in total operating income, which mirrors the sales figures. The total expenditure has also risen, reaching 7,706.35 Cr in Mar'25, up from 5,609.44 Cr in Mar'22. Operating profit (PBDIT) has shown improvement, climbing from 1,225.46 Cr in Mar'22 to 1,579.64 Cr in Mar'25, with the operating profit margin increasing to 15.79% in Mar'25 from 14.48% in Mar'22. Despite this, profit before tax has been volatile, with a notable drop to -174.48 Cr in Mar'23 before recovering to 341.71 Cr in Mar'25. Profit after tax has also fluctuated, moving from a high of 316.93 Cr in Mar'22 to a loss of 240.79 Cr in Mar'23, and then to a modest profit of 18.20 Cr in Mar'25. The consolidated net profit reflects this trend, showing a recovery from -186.46 Cr in Mar'23 to 91.13 Cr in Mar'25. On the balance sheet, total liabilities increased from 12,499.77 Cr in Mar'22 to 15,284.46 Cr in Mar'25, while total assets rose correspondingly, indicating a growing scale of operations. Cash flow from operating activities has been variable, peaking at 1,004.00 Cr in Mar'24 before dropping to 892.00 Cr in Mar'25, with net cash outflow recorded in Mar'25. Overall, Piramal Pharma's financial performance demonstrates resilience and growth potential despite some fluctuations in profitability.

Is Piramal Pharma overvalued or undervalued?

As of November 27, 2025, Piramal Pharma is fairly valued with a PE ratio of -557.34, an EV to EBITDA of 24.82, and a Price to Book Value of 3.07, contrasting with peers like Sun Pharma and Cipla, while experiencing a year-to-date stock decline of 29.83% compared to the Sensex's gain of 9.70%.

As of 27 November 2025, Piramal Pharma's valuation grade has moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a PE ratio of -557.34, an EV to EBITDA of 24.82, and a Price to Book Value of 3.07. <BR><BR>In comparison to its peers, Piramal Pharma's valuation stands out against Sun Pharma, which is considered expensive with a PE ratio of 37.62, and Cipla, which is rated attractive with a PE ratio of 22.67. Notably, Piramal's negative PE ratio indicates significant challenges, while its EV to EBITDA ratio is comparable to some peers but still reflects high leverage. Recent stock performance shows a decline of 29.83% year-to-date, contrasting sharply with the Sensex's gain of 9.70%, further emphasizing the company's current valuation context.

Who are the top shareholders of the Piramal Pharma?

The top shareholders of Piramal Pharma include the Sri Krishna Trust with 26.62%, foreign institutional investors holding 31.49%, and mutual funds with 12.73%. The highest public shareholder is Ca Alchemy Investments at 18%, while individual investors own 13.11%.

The top shareholders of Piramal Pharma include the promoters, who hold the majority of the shares. Specifically, the Sri Krishna Trust, represented by Mr. Ajay G. Piramal and Dr. (Mrs.) Swati A. Piramal, has the highest holding at 26.62%. <BR><BR>In addition to the promoters, foreign institutional investors (FIIs) hold a significant stake of 31.49%, while mutual funds are represented by 25 schemes, accounting for 12.73% of the shares. The highest public shareholder is Ca Alchemy Investments, which holds 18%. Individual investors collectively own 13.11% of the company.

When is the next results date for Piramal Pharma?

No Upcoming Board Meetings

Has Piramal Pharma declared dividend?

Piramal Pharma Ltd has declared a 1% dividend, amounting to ₹0.1 per share, with an ex-date of July 12, 2024. The dividend yield is 0.05%, and while the company has shown strong returns over the past year and two years, recent performance has been negative in the last six months.

Piramal Pharma Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: Jul-12-2024<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.43%, the dividend return was 0%, resulting in a total return of -22.43%.<BR><BR>Over the past year, the price return was 39.89%, the dividend return was 0.06%, leading to a total return of 39.95%.<BR><BR>In the 2-year period, the price return was 143.03%, the dividend return was 0.11%, which resulted in a total return of 143.14%.<BR><BR>For the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, the price return and dividend return remained at 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Piramal Pharma has declared a dividend, the returns over the past periods show significant variability, particularly with strong returns in the 1 and 2-year periods compared to negative returns in the recent 6-month period. The dividend yield is relatively low, indicating that while there is a dividend, it may not be a primary attraction for investors.